Analysts expect AcelRx Pharmaceuticals (NASDAQ:ACRX) to report ($0.24) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for AcelRx Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.24) and the highest is ($0.23). AcelRx Pharmaceuticals posted earnings per share of ($0.34) in the same quarter last year, which would indicate a positive year-over-year growth rate of 29.4%. The business is scheduled to announce its next quarterly earnings report on Monday, May 14th.
According to Zacks, analysts expect that AcelRx Pharmaceuticals will report full-year earnings of ($0.98) per share for the current fiscal year, with EPS estimates ranging from ($1.01) to ($0.95). For the next financial year, analysts anticipate that the company will report earnings of ($0.84) per share, with EPS estimates ranging from ($0.97) to ($0.70). Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover AcelRx Pharmaceuticals.
AcelRx Pharmaceuticals (NASDAQ:ACRX) last announced its quarterly earnings results on Thursday, March 8th. The specialty pharmaceutical company reported ($0.20) EPS for the quarter, meeting the consensus estimate of ($0.20). The firm had revenue of $0.74 million for the quarter, compared to analysts’ expectations of $2.90 million.
Shares of AcelRx Pharmaceuticals stock traded up $0.03 during trading on Friday, hitting $2.20. 160,518 shares of the stock traded hands, compared to its average volume of 438,976. The firm has a market cap of $109.43, a P/E ratio of -1.98 and a beta of 2.42. The company has a current ratio of 4.64, a quick ratio of 4.57 and a debt-to-equity ratio of -0.31. AcelRx Pharmaceuticals has a 52-week low of $1.55 and a 52-week high of $5.75.
An institutional investor recently raised its position in AcelRx Pharmaceuticals stock. Geller Family Office Services LLC increased its position in shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) by 175.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 275,000 shares of the specialty pharmaceutical company’s stock after buying an additional 175,000 shares during the period. AcelRx Pharmaceuticals comprises approximately 0.3% of Geller Family Office Services LLC’s holdings, making the stock its 17th largest holding. Geller Family Office Services LLC owned about 0.55% of AcelRx Pharmaceuticals worth $557,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 9.20% of the company’s stock.
WARNING: This story was originally posted by Ticker Report and is the property of of Ticker Report. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://www.tickerreport.com/banking-finance/3335749/0-24-eps-expected-for-acelrx-pharmaceuticals-acrx-this-quarter.html.
AcelRx Pharmaceuticals Company Profile
AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.